Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE VISCOUS versus POLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE VISCOUS versus POLOCAINE.
LIDOCAINE VISCOUS vs POLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7, Nav1.8) in neuronal membranes, inhibiting depolarization and propagation of action potentials, thereby producing local anesthesia. It also has antiarrhythmic properties (class IB) by blocking sodium channels in cardiac myocytes.
Local anesthetic that stabilizes the neuronal membrane by inhibiting the influx of sodium ions, thereby blocking nerve impulse propagation.
15 mL (300 mg) orally every 3 hours as needed for pain; maximum 8 doses per 24 hours.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (up to 3 hours in hepatic impairment). Clinically, redistribution half-life (~6 min) determines duration of action after short infusions.
Terminal elimination half-life approximately 1.5-2.0 hours in adults; prolonged to 3-5 hours in hepatic impairment and neonates.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; <10% biliary/fecal. Metabolites include monoethylglycinexylidide (MEGX) and glycinexylidide (GX).
Hepatic metabolism to 2,6-xylidine and 4-hydroxy-2,6-xylidine; <10% excreted unchanged in urine; approximately 70-80% of metabolites excreted renally, with <5% in feces.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic